Funding for this research was provided by:
Nordic Cancer Union, Icelandic Cancer Society. SAN is supported by the Peter Gilgan Centre for Cancer in Women.
Received: 9 March 2020
Revised: 6 August 2020
Accepted: 25 August 2020
First Online: 17 September 2020
Ethics approval and consent to participate
: The study was approved by The Danish Data Protection Agency (2009-41-3611) and the Danish Ethical Committee (registration number 33483), The National Bioethics Committee of Iceland (VSN-13-133-V5), The Norwegian Data Inspectorate (ref. 2001/2988-2) and Ethical Review Board (ref. S-02030) and (ref. 2015/2382) and The Regional Ethical Review Board in Lund. All Norwegian and Swedish patients consented to the study. The Danish Ethical Committee gave a waiver concerning consent to this study, and genetic testing is part of routine diagnostics in Denmark. In Iceland, genetic testing for the majority of patients (historical cohort) was done using paraffin- embedded tumour specimens from pathology archives, based on permission from the National Bioethics Committee of Iceland. The remaining Icelandic patients consented to the study.
: Our paper does not contain any individual person’s data in any form.
: The datasets generated and/or analysed during the current study are not publicly available, due to protection of the privacy of <i>BRCA2</i> mutation carrier patients, but are available from the corresponding author on reasonable request.
: Steven A. Narod is an Editorial board member to <i>British Journal of Cancer</i>.
: The study was funded by the Nordic Cancer Union and the Icelandic Cancer Society. S.A.N. is supported by the Peter Gilgan Centre for Cancer in Women.